NEJM retracts pivotal data for Amgen's Tavneos, adding new hurdle for the autoimmune drug

The New England Journal of Medicine has withdrawn the pivotal data that supported Amgen’s autoimmune therapy Tavneos.

The retraction was requested by two academic authors who raised concerns about the study, prompting the journal to remove the findings.

The removal creates another obstacle for Tavneos, which has already faced challenges in its development and market positioning.

Investors and clinicians will be watching how the setback influences ongoing trials and any future regulatory submissions.